Regeneus Ltd (ASX: RGS) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Regeneus Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.53 million
P/E Ratio 9.43
Dividend Yield 0.00%
Shares Outstanding 306.44 million
Earnings per share -0.002
Dividend per share N/A
Year To Date Return 66.67%
Earnings Yield 10.61%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Regeneus Ltd (ASX: RGS)
    Latest News

    No posts found.

    RGS ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Regeneus Ltd

    Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. It mainly develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus,across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing. The company has one operating segment being the development of innovative cell-based therapies to address significant unmet medical needs in human and veterinary health.

    RGS Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    27 Mar 2024 $0.01 $0.00 0.00% 206,029 $0.01 $0.01 $0.01
    22 Mar 2024 $0.01 $0.00 0.00% 125,000 $0.01 $0.01 $0.01
    21 Mar 2024 $0.01 $0.00 0.00% 70,193 $0.01 $0.01 $0.01
    20 Mar 2024 $0.01 $0.00 0.00% 468,948 $0.01 $0.01 $0.01
    15 Mar 2024 $0.01 $0.00 0.00% 1,000 $0.01 $0.01 $0.01
    13 Mar 2024 $0.01 $0.00 0.00% 220,000 $0.01 $0.01 $0.01
    07 Mar 2024 $0.01 $0.00 0.00% 10,000 $0.01 $0.01 $0.01
    04 Mar 2024 $0.01 $0.00 0.00% 433,634 $0.01 $0.01 $0.01
    29 Feb 2024 $0.01 $0.00 0.00% 1 $0.01 $0.01 $0.01
    28 Feb 2024 $0.01 $0.00 0.00% 20,641 $0.01 $0.01 $0.01

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Barry George Sechos Non-Executive DirectorNon-Executive Chairman Jul 2012
    Mr Sechos has served on the Board since 2012 and has over 35 years experience as a director, business executive with experience in investment and asset management. Barry is Executive Director of the Sherman Group (an early-stage investor in the Company) and sits on the board of many Sherman Group companies and investee companies. His previous directorship includes Concentrated Leaders Fund Ltd (resigned 31 August 2021) and Phoslock Environmental Technologies Ltd (resigned 5 September 2023).
    Professor Graham Vesey Chief Scientific OfficerExecutive Director Aug 2007
    Mr Vesey is a biotechnology entrepreneur, technology innovator and inventor. Graham was a co-founder and Executive Director of the successful biotech company, BTF, which was sold to bioMerieux in 2007. Graham is an Adjunct Professor at Macquarie University.
    Mr Leo Lee Non-Executive Director Jan 2019
    Mr Lee brings more than 20 years experience in pharmaceutical innovation, commercialisation, regulation and policy development and has worked in North America and Asia. Mr Lee currently serves as Country President, Japan, for Novartis and prior to his CEO role at Regeneus, he was President, Japan, for Merck KGaA. Prior to this, he served as President, Japan, for Allergan plc, a global pharmaceutical company. Leo has held sales and commercial roles in Merck & Co., IQVIA and Accelrys, Inc.
    Mr Karolis Rosickas Chief Executive Officer Nov 2020
    -
    Ms Hang Ling (Helen) Leung Company Secretary Jul 2021
    -
    Karolis Rosickas Chief Executive Officer
    -
    Hang Ling (Helen) Leung Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 32,103,469 14.26%
    Bnp Paribas Nominees Pty Ltd 27,065,582 7.95%
    Citicorp Nominees Pty Limited 21,655,145 7.06%
    Mrs Julia Caroline Hughes 13,648,692 4.47%
    I Rom Group Co Ltd 9,144,043 2.98%
    Sunreef Pty Ltd 8,907,834 2.25%
    Super Dino Pty Ltd 8,805,740 1.72%
    Dr Paul Francis Morton 5,345,031 1.70%
    Mr Thomas Georg Mechtersheimer 5,255,519 1.59%
    Mr Simon Clarkson 5,216,726 1.31%
    Bnp Paribas Noms Pty Ltd 4,806,797 0.99%
    MLB Holdings Pty Ltd 4,000,000 0.84%
    Bubbling Wells Pty Ltd 2,500,000 0.82%
    Mcguire Family Holdings Pty Ltd 2,350,000 0.77%
    Liddle Investments Group Pty Ltd 2,202,859 0.72%
    Dr Marc Ronald Wilkins 2,020,676 0.66%
    Kbross Pty Ltd 2,000,000 0.65%
    The Quist Group Pty Ltd 1,760,608 0.57%
    Mark Timney 1,750,000 0.57%
    Jeffrey Chun Kim Khoo 1,750,000 0.57%
    Towns Corporation Pty Ltd 1,675,000 0.54%

    Profile

    since

    Note